Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk.

ABSTRACT:

SUBMITTER: Lesniak RK 

PROVIDER: S-EPMC9643380 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature